Primary Progressive Multiple Sclerosis (PPMS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Primary progressive multiple sclerosis (PPMS) stands out among the various forms of multiple sclerosis due to its unique characteristic of presenting as a progressively worsening condition from the onset of the disease. In contrast to relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), where symptoms come and go in episodes, PPMS is marked by a continuous deterioration of neurological function. Approximately 10% of all multiple sclerosis patients receive a diagnosis of PPMS, making it a relatively less common but impactful subtype of the disease. The precise cause of PPMS remains unknown, adding to the complexity of understanding and treating this form of multiple sclerosis. Patients typically receive a PPMS diagnosis in their mid-to-late 30s, a stage of life where the impact on daily functioning and quality of life can be particularly challenging. Noteworthy is the observation that primary progressive multiple sclerosis may exhibit a higher prevalence in men compared to the relapsing/remitting disease group. This potentially leads to an equal male-to-female sex ratio or even a slight male preponderance among individuals with PPMS. Symptomatically, individuals living with PPMS often experience manifestations similar to those with relapsing forms of multiple sclerosis. However, weakness in leg muscles and difficulties with walking tend to be more prevalent in PPMS, further distinguishing it from other subtypes. One of the challenges in managing PPMS is the need for more understanding of its immunological findings compared to other forms of the disease. This knowledge gap underscores the need for further research to elucidate the underlying mechanisms driving the progressive nature of PPMS. In March 2017, the US Food and Drug Administration approved Ocrevus (ocrelizumab) to address relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) in adult patients. This is the first drug approved by the FDA for PPMS.

Thelansis’s “Primary Progressive Multiple Sclerosis (PPMS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Progressive Multiple Sclerosis (PPMS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Primary Progressive Multiple Sclerosis (PPMS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Primary Progressive Multiple Sclerosis (PPMS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Primary Progressive Multiple Sclerosis (PPMS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033